MOLN
Molecular Partners AGNASDAQHealthcare$3.85-3.87%ClosedMarket Cap: $144.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.50
P/S
0.00
EV/EBITDA
-0.52
DCF Value
$2.68
FCF Yield
-42.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-60.1%
ROA
-60.4%
ROIC
-62.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-12.6M | $-12.6M | $-0.33 | — |
| FY 2025 | $0.00 | NaN% | $-58.1M | $-61.7M | $-1.65 | — |
| Q3 2025 | $0.00 | -Infinity% | $-12.0M | $-11.8M | $-0.32 | — |
| Q2 2025 | $0.00 | -Infinity% | $-17.3M | $-20.4M | $-0.55 | — |
| Q1 2025 | $0.00 | -Infinity% | $-16.1M | $-16.8M | $-0.45 | — |
| Q4 2024 | $0.00 | -Infinity% | $-14.8M | $-11.2M | $-0.33 | — |
| FY 2024 | $5.0M | -855.8% | $-61.2M | $-54.0M | $-1.59 | — |
| Q3 2024 | $681.0K | -1495.3% | $-14.6M | $-16.4M | $-0.49 | — |
| Q2 2024 | $1.6M | -743.8% | $-16.0M | $-15.1M | $-0.45 | — |
| Q1 2024 | $2.7M | -415.1% | $-15.9M | $-11.3M | $-0.34 | — |
| Q4 2023 | $1.0M | -1054.1% | $-16.6M | $-19.8M | $-0.60 | — |
| FY 2023 | $7.0M | -579.8% | $-61.1M | $-62.0M | $-1.89 | — |